Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Visceral Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Visceral Pain - Pipeline Review, H2 2016', provides an overview of the Visceral Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Visceral Pain - The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects - The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Visceral Pain Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Visceral Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Visceral Pain Overview 7 Therapeutics Development 8 Pipeline Products for Visceral Pain - Overview 8 Pipeline Products for Visceral Pain - Comparative Analysis 9 Visceral Pain - Therapeutics under Development by Companies 10 Visceral Pain - Therapeutics under Investigation by Universities/Institutes 11 Visceral Pain - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Visceral Pain - Products under Development by Companies 14 Visceral Pain - Products under Investigation by Universities/Institutes 15 Visceral Pain - Companies Involved in Therapeutics Development 16 Addex Therapeutics Ltd 16 Astellas Pharma Inc. 17 Chromocell Corporation 18 GIcare Pharma Inc 19 Grunenthal GmbH 20 Medestea Research & Production S.p.A. 21 Neurim Pharmaceuticals Ltd 22 Pfizer Inc. 23 Visceral Pain - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 30 Drug Profiles 32 ADX-71441 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 ADX-71743 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ASP-7663 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 CC-8464 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 GIC-1002 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 MED-1101 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 NEO-5937 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 NeuP-12 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 piromelatine - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 PR-38 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 RO-656570 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 SBFI-26 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 URB-937 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Visceral Pain - Dormant Projects 53 Visceral Pain - Discontinued Products 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for Visceral Pain, H2 2016 8 Number of Products under Development for Visceral Pain - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2016 16 Visceral Pain - Pipeline by Astellas Pharma Inc., H2 2016 17 Visceral Pain - Pipeline by Chromocell Corporation, H2 2016 18 Visceral Pain - Pipeline by GIcare Pharma Inc, H2 2016 19 Visceral Pain - Pipeline by Grunenthal GmbH, H2 2016 20 Visceral Pain - Pipeline by Medestea Research & Production S.p.A., H2 2016 21 Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 22 Visceral Pain - Pipeline by Pfizer Inc., H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Number of Products by Stage and Target, H2 2016 26 Number of Products by Stage and Mechanism of Action, H2 2016 28 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Visceral Pain - Dormant Projects, H2 2016 53 Visceral Pain - Dormant Projects (Contd..1), H2 2016 54 Visceral Pain - Dormant Projects (Contd..2), H2 2016 55 Visceral Pain - Discontinued Products, H2 2016 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
